A team of physicists at the Institut Lumière Matière (CNRS/Université Claude Bernard Lyon 1), in collaboration with the Cancer Research Center of Lyon (CNRS/INSERM/ Université Claude Bernard Lyon 1/Centre Léon Bérard/Hospices civils de Lyon), has demonstrated the potential, for oncology, of an imaging technique based only on the physical properties of tumors. It can differentiate populations of malignant cells and monitor how effective an anticancer treatment is. These results, published in Physical Review Letters on January 8, 2019, should help in the design of new therapeutic molecules and in the personalization of treatments.
Despite a good understanding of the biology of cancer, 90% of experimental drugs fail during clinical trials. It is also increasingly suspected that the mechanical properties of tumors influence disease progression, and treatment efficacy. Although we can evaluate tumor elasticity globally, it is more difficult to measure local rigidity deep down and to see whether the core of the tumor resists the penetration of therapeutic liquids. To probe these physical properties, the researchers have used a noncontact imaging technique that does not require the use of contrast agents – therefore that does not disturb tissue function – that exploits natural infinitesimal vibrations of matter.
To recapitulate the behavior of colorectal tumors in vitro, the researchers created organoids, spheres with diameter 0.3 mm formed by the aggregation of tumor cells. They focused a red laser beam onto these objects. The infinitesimal vibrations of the sample, generated by thermal agitation, modify very slightly the color of the light beam that exits the sample. By analyzing this light, a map of the mechanical properties of the model tumors is created: the more rigid the area scanned by the laser, the faster the vibrations and, in a manner comparable to the Doppler effect (the mechanism that makes a siren sound increasingly shrill as it gets closer), the greater the color change.
From organoids composed of two cell lines with different malignancies, the researchers have shown that they could distinguish the two cell types from their mechanical properties. Such information is crucial because it may allow diagnosis from biopsy analysis to be refined and offer better assessment of tumor grade. Local variations in mechanical properties after a drug treatment have also been monitored using this technique: the center of the tumor remains rigid longer than the edge, demonstrating the treatment’s efficacy gradient. So local measurement of mechanical properties could confirm the total destruction of the tumor and help in choosing as low a treatment dose and duration as possible.
This approach allows exploring the impact of mechanical properties on the therapeutic response. It should lead to more predictive in vitro tumor models for testing new therapeutic molecules and for combined therapies, which act for example on tissue rigidity to accelerate the penetration of active molecules in the center of the tumor. It could also provide new indicators to guide clinicians in personalization of therapies.
Learn more: Physics can show us the inside of tumors
The Latest on: Personalized cancer treatment
via Google News
The Latest on: Personalized cancer treatment
- Bronx girl leaves hospital after years of cancer treatmenton May 16, 2022 at 2:58 pm
It’s been an incredibly tough journey for a 5-year-old Bronx girl who just left the Children’s Hospital at Montefiore on Monday after three years of cancer treatment. Djream ...
- Using CAR T-cell therapy, scientists seek cure for cancer at the molecular levelon May 16, 2022 at 4:59 am
He and his team use a combination of advanced microscopy, custom-designed tools, and ingenuity to study immunology at the molecular level, and they apply that knowledge to create novel treatments. “I ...
- Advancing Personalized Medicine Through Computationon May 12, 2022 at 2:33 pm
A multi-institution team including Samir Khuller, Saba Ahmadi and Pattara Sukprasert developed combinatorial optimization software called MadHitter to identify cell membrane protein targets for ...
- Smoking-cessation program that targets cancer patients effectiveon May 11, 2022 at 3:51 pm
Researchers at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have found a way to help more patients who want to stop smoking. The successful ...
- New smoking-cessation program helps more cancer patients to quit successfullyon May 11, 2022 at 3:45 pm
"Traditionally, there have been three pillars of cancer treatment," Ramsey said ... And they're continuing to home in on personalized care recommendations, including for patients at risk for lung ...
- Evaxion Biotech successfully produces personalized cancer immunotherapies in phase 1/2a trial for EVX-02on May 11, 2022 at 3:30 am
Evaxion Biotech A/S, a clinical-stage biotechnology, announced that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the phase 1/2a clinical ...
- Personalized cancer therapy co OncoHost raises $35mon May 11, 2022 at 2:53 am
Israeli personalized cancer therapy developer OncoHost has announced the completion of an oversubscribed $35 million Series C financing round led by ALIVE Israel HealthTech VC with participation from ...
- It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the openon May 10, 2022 at 11:14 am
After years of delays and excuses, Northwest Biotherapeutics finally disclosed on Tuesday the final results from a late-stage clinical trial of its personalized cancer vaccine administered to patients ...
- Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02on May 10, 2022 at 5:49 am
We have again demonstrated our capabilities to timely deliver personalized cancer treatment tailored to the unique cancer profile of every patient in a clinical trial.” The production process of ...
- $35 Million In New Funding For AI To Personalize Cancer Treatmenton May 10, 2022 at 5:00 am
OncoHost raises $35 million to further develop and test its precision oncology platform, combining proprietary bioinformatics, signal processing, and machine learning.
via Bing News